News

The NIH anticipates spending $150 million over five years to renew its Pharmacogenetics Research Network.

BioForce was awarded $500,000 to support commercialization of its award-winning NanoArrayer™ technology for production of ultraminiaturized biomedical tests and devices.

The cluster, called NanoBio, aims to foster the technological and economical development in the bioengineering field, taking advantage of the CEA’s 10-years experience in biochips and bioMEMS research.

Patients with a specific combination of polymorphisms in genes responsible for the production of C-reactive protein (CRP) and interleukin-6 (IL-6) suffered stroke at three times higher rate.

The patent application is being filed in conjunction with major research institutions in the Houston area, with Power3 having an exclusive license to commercialize the technology involved.

Ciphergen will provide its suite of proteomic solutions designed for biomarker discovery and development of assays, to analyze patients' tumor cyst fluid and blood samples collected at University of Kentucky Healthcare.

Scientists have announced that they are investigating a class of pharmaceuticals that may well improve memory function, including those with Alzheimer's disease, and address some of the underlying causes of memory loss rather than today's drugs that simply treat symptoms.

Reaxa Limited, a new catalyst technologies company, formally commenced trading on the 22 June 2005 following a successful spin-out from Avecia.

Accelrys, has announced the launch of a number of next-generation products across its entire portfolio of software for pharmaceutical, chemical, and materials researchers.